Homepage Top Section1

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients

The conditional marketing authorisation is based on the recommendation of the European Medicines Agency (EMA) for use of the Covid-19 Vaccine Moderna for active immunisation to prevent Covid-19

Under the deal, LakePharma will produce Akston’s adjuvanted Covid-19 vaccine candidate (AKS-452), which is slated to start phase 1/2 clinical testing later this month. LakePharma president and CEO

The approval has been given following the recommendation of its Subject Expert Committee (SEC). Additionally, recommendation has been made for the approval of the Phase III clinical trial

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase designed to be used as subcutaneous (SC) injection. Phesgo integrates the same monoclonal antibodies as

The deal, which covers commercial, clinical and research-stage oncology portfolio, consists of an upfront payment of $1.8bn. Agios is also eligible to secure up to $200m in regulatory

Based in Cambridge of Massachusetts, Cadent Therapeutics is involved in the development of therapies to treat cognitive, mood, and movement disorders. Cadent will secure a $210m upfront payment,

PAH is a rare and chronic progressing disorder characterised by the narrowing of small pulmonary arteries and inflated blood pressure in the pulmonary circulation. Sotatercept, an investigational reverse-remodelling

The BNT162b2 vaccine has been granted authorisation under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada is